Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up.
Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).
Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.